{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-011757","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.777966+00:00","generated_at":"2026-05-15T06:57:43.614596+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%","bullets":["Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.","Domestic sales $9.7M (+35.7%); international sales $0.6M (-30.2%).","Tri-Shield First Defense sales $7.9M (+38.5%); Dual-Force & Other $2.5M (+4.4%).","CFO notes prior backorder situation still complicates comparisons but operational progress shown.","Conference call scheduled for May 15, 2026 at 9:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-011757","json":"https://secwatch.observer/filing/0001437749-26-011757.json","markdown":"https://secwatch.observer/filing/0001437749-26-011757.md","text":"https://secwatch.observer/filing/0001437749-26-011757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/0001437749-26-011757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/iccc20260408_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:57:43.614596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f5efa55bdef68e7f043ef2ccace3f1e8db0f620","claim":"IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue $10.4 million.","evidence_excerpt":"health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: ● Domestic sales were $9.7 million in 2026, a 35.7% increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/0001437749-26-011757-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$10.4 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}